Developing Pan-β-coronavirus Vaccines Against Emerging SARS-CoV-2 Variants of Concern

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2022 Feb 7

PMID 35125310

Authors

Shan Su

Weihua Li

Shibo Jiang

Affiliations

Soon will be listed here.

Abstract

The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.

Citing Articles

Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle.

Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S PNAS Nexus. 2024; 3(12):pgae529.

PMID: 39677368 PMC: 11645456. DOI: 10.1093/pnasnexus/pgae529.

Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP.

Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S bioRxiv. 2024; .

PMID: 39253464 PMC: 11383317. DOI: 10.1101/2024.08.28.608716.

Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion.

Rodrigues K, Zhang Y, Aung A, Morgan D, Maiorino L, Yousefpour P bioRxiv. 2024; .

PMID: 39229011 PMC: 11370361. DOI: 10.1101/2024.08.19.608655.

Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.

Bean D, Monroe J, Liang Y, Borberg E, Senussi Y, Swank Z Sci Transl Med. 2024; 16(751):eado7588.

PMID: 38865483 PMC: 11565543. DOI: 10.1126/scitranslmed.ado7588.

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.

Xu K, Li J, Lu X, Ge X, Wang K, Wang J Vaccines (Basel). 2024; 12(1).

PMID: 38250873 PMC: 10819607. DOI: 10.3390/vaccines12010060.

References

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

Su S, Du L, Jiang S . Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2020; 19(3):211-219. PMC: 7566580. DOI: 10.1038/s41579-020-00462-y. View

Elhazmi A, Al-Tawfiq J, Sallam H, Al-Omari A, Alhumaid S, Mady A . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series. Travel Med Infect Dis. 2021; 41:102026. PMC: 7955802. DOI: 10.1016/j.tmaid.2021.102026. View

Cohen A, Gnanapragasam P, Lee Y, Hoffman P, Ou S, Kakutani L . Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. 2021; 371(6530):735-741. PMC: 7928838. DOI: 10.1126/science.abf6840. View

Li Y, Zhang Z, Yang L, Lian X, Xie Y, Li S . The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. iScience. 2020; 23(8):101400. PMC: 7386421. DOI: 10.1016/j.isci.2020.101400. View

van Boheemen S, de Graaf M, Lauber C, Bestebroer T, Raj V, Zaki A . Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012; 3(6). PMC: 3509437. DOI: 10.1128/mBio.00473-12. View

Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q . RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020; 5(1):282. PMC: 7691975. DOI: 10.1038/s41392-020-00402-5. View

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

10.

Li D, Edwards R, Manne K, Martinez D, Schafer A, Alam S . In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021; 184(16):4203-4219.e32. PMC: 8232969. DOI: 10.1016/j.cell.2021.06.021. View

11.

Saunders K, Lee E, Parks R, Martinez D, Li D, Chen H . Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021; 594(7864):553-559. PMC: 8528238. DOI: 10.1038/s41586-021-03594-0. View

12.

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F . SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020; 587(7833):270-274. DOI: 10.1038/s41586-020-2598-9. View

13.

Tan C, Chia W, Young B, Zhu F, Lim B, Sia W . Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N Engl J Med. 2021; 385(15):1401-1406. PMC: 8422514. DOI: 10.1056/NEJMoa2108453. View

14.

. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4):536-544. PMC: 7095448. DOI: 10.1038/s41564-020-0695-z. View